KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 61.51%.

  • Halozyme Therapeutics' EBITDA Margin rose 52600.0% to 61.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 59.33%, marking a year-over-year increase of 89800.0%. This contributed to the annual value of 54.32% for FY2024, which is 136100.0% up from last year.
  • Per Halozyme Therapeutics' latest filing, its EBITDA Margin stood at 61.51% for Q3 2025, which was up 52600.0% from 62.15% recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year EBITDA Margin high stood at 68.19% for Q2 2021, and its period low was 22.35% during Q2 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 53.44% (2025), whereas its average is 50.84%.
  • In the last 5 years, Halozyme Therapeutics' EBITDA Margin soared by 697000bps in 2021 and then crashed by -458300bps in 2022.
  • Halozyme Therapeutics' EBITDA Margin (Quarter) stood at 55.42% in 2021, then dropped by -26bps to 41.05% in 2022, then increased by 7bps to 43.92% in 2023, then soared by 34bps to 58.89% in 2024, then grew by 4bps to 61.51% in 2025.
  • Its last three reported values are 61.51% in Q3 2025, 62.15% for Q2 2025, and 53.44% during Q1 2025.